TABLE 3 

Test and permutated Q2 (quality assessment statistic) scores for OPLS-DA models of 1H HR-MAS spectra of M. smegmatis mc2 155a

TreatmentQ2Q2 (permutated)
Tyloxapol (0.025%)0.866−0.377
D-LAK120-A0.769−0.423
D-LAK120-HP130.729−0.360
Rifampin0.581−0.426
Rifampin + D-LAK120-A0.763−0.410
Rifampin + D-LAK120-HP130.430−0.429
Capreomycin0.881−0.347
Capreomycin + D-LAK120-A0.775−0.367
Capreomycin + D-LAK120-HP130.823−0.344
  • a Comparison of test and permutated Q2 scores for cross-validated OPLS-DA models comparing 1H HR-MAS spectra of unchallenged M. smegmatis mc2 155 with those obtained for bacteria under the indicated conditions.